Miscellaneous
Lead investigator Philip Mease outlines the results of a phase IIb trial supporting further development of the anti-interleukin-23p19 monoclonal antibody tildrakizumab for the treatment of psoriatic arthritis. Find more on Medicine Matters rheumatology This content was originally published on Medicine Matters rheumatology (https://rheumatology.medicinematters.com/) on June 12, 2019.